Pacer Advisors Inc. Acquires 2,965,310 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Pacer Advisors Inc. lifted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 130,918.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,967,575 shares of the biopharmaceutical company’s stock after acquiring an additional 2,965,310 shares during the period. Pacer Advisors Inc. owned 2.51% of Catalyst Pharmaceuticals worth $45,968,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of CPRX. GAMMA Investing LLC grew its holdings in shares of Catalyst Pharmaceuticals by 72.9% during the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 819 shares during the last quarter. CWM LLC grew its stake in Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 3,549 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Catalyst Pharmaceuticals during the 2nd quarter worth $70,000. Headlands Technologies LLC purchased a new position in shares of Catalyst Pharmaceuticals in the 1st quarter worth about $154,000. Finally, XTX Topco Ltd grew its position in Catalyst Pharmaceuticals by 7.5% during the second quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 773 shares during the period. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Trading Down 2.6 %

Shares of CPRX opened at $20.79 on Friday. Catalyst Pharmaceuticals, Inc. has a 1-year low of $11.55 and a 1-year high of $21.67. The firm’s 50-day moving average price is $18.90 and its 200-day moving average price is $16.82. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of 38.50, a PEG ratio of 3.10 and a beta of 0.75.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.13. The company had revenue of $122.71 million during the quarter, compared to analysts’ expectations of $111.76 million. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. On average, research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on CPRX shares. Oppenheimer restated an “outperform” rating and issued a $29.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, June 6th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Truist Financial lifted their target price on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, August 9th. HC Wainwright upped their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Citigroup raised their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $29.50.

Insider Transactions at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the transaction, the director now owns 348,874 shares in the company, valued at $7,012,367.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 36,058 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the sale, the insider now owns 12,369 shares of the company’s stock, valued at $227,836.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares in the company, valued at approximately $7,012,367.40. The disclosure for this sale can be found here. Insiders sold a total of 201,058 shares of company stock valued at $4,018,188 in the last quarter. 11.00% of the stock is owned by insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.